Merck has filed its immunotherapy drug Keytruda for use in lung cancer patients ... As with all targeted therapies, the PD-L1 test needs a companion diagnostic to be developed and approved.

including melanoma and non-small cell lung cancer (NSCLC), over six months. The main aim of the study is to assess the safety of mRNA-4359 and its ability to stimulate antibodies against PD-L1 and ...

Genetic testing has emerged as a crucial tool ... Checkpoint inhibitors have revealed their potentials in the treatment of lung cancer with PD-L1 expression rates in patients.